With Oncology Drugs On The Way, AstraZeneca Sets The Stage For New Launches
Executive Summary
U.S. President Paul Hudson says AstraZeneca is building specialty commercial team ahead of new oncology launches; MedImmune seals new deals in its quest for winning combinations in immuno-oncology.
You may also be interested in...
AstraZeneca, Flying Solo, Sees Momentum Take Off In Diabetes
The company launched three diabetes drugs in 2014, just after breaking off a joint venture with Bristol-Myers and taking over full control of the business. U.S. President Paul Hudson talked about the evolution of AstraZeneca’s diabetes business – and where it stands today – in a recent interview.
AstraZeneca Staking Its Growth On Oncology; Now It Needs Cancer Drugs
AstraZeneca has an ambitious agenda to become a leader in oncology. The company’s notably improved pipeline is broad, but winning will require AstraZeneca to come from behind to uncover the best combinations ahead of the competition.
AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key
AstraZeneca is in the midst of a concerted push in oncology, but many of its top contenders are in crowded classes. The firm sees its future in the possibilities of combinations with immunotherapies.